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plates. Gels without Hap were used as controls. The gels were kept in
culture for 3 weeks in αMEM medium containing 10%FCS. Gel contraction
and cell viability, morphology and metabolism were analyzed.
Results: Gels, attached to surface plates after fabrication, became free-
ﬂoating gels contracted from day 3, only in the presence of cells. A linear
rapid contraction phase was observed until day 7, then a very slow con-
traction phase took place. The incorporation of Hap improved gel stability
as compared to collagen gels without Hap.
Total DNA increased two times from day 3 to day 21, reﬂecting cell
proliferation inside gels. Moreover, while cell metabolism increased all
over the culture period, an important increase was observed after 3 weeks.
Cells cultured in gels showed elongated spindle-shape morphology and a
few dead cells were observed all over the experiment. Microscopy images
showed that cells were randomly distributed on the gel. After proliferation
cells were connected, mainly at the gel surface, which could stabilize
collagen contraction.
Conclusions: This study shows the feasibility and biocompatibility of hy-
droxyapatite supplemented collagen gels for the culture of mesenchymal
stem cells. They could be used as carriers for cell delivery in osteoarticular
regenerative medicine.
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PRENATAL DEVELOPMENTAL HEALINGWITH INTRA-ARTICULAR
GROWTH HORMONE (IAGH) INJECTIONS TREATS A VARIETY OF
OSTEOARTHRITIC AND RHEUMATOID JOINTS WITH A SUCCESS RATE OF
75% TO 95% AND NO COMPLICATIONS
A.R. Dunn
Mt. Sinai Med. Ctr., Miami Beach, FL
Purpose: To utilize the prenatal developmental scar-free healing promoted
by intra-articular growth hormone (IAGH) injections. The basic science
demonstrates that pre-natal developmental healing (PDH) occurs without
bleeding, clot formation and the in-pouring of inﬂammatory cells and
ﬁbroblasts, the cascade of post-natal healing. PDH produces real articular
cartilage and no ﬁbrocartilage. A study of 66 patients with advanced
osteoarthritis of the knee treated with IAGH resulted in 87 per cent
good and excellent results and the patients did not need total knee
arthroplasty (TKA). In light of these results the author has treated many
other joints with equally good to excellent results. Methodology including
pre-treatment testing and results are here reported.
Methods: Every patient was evaluated before treatment with blood tests,
X-rays and MRI’s. Weight had to be within one standard deviation of
normal.
Patients were instructed in exercising and use of crutches during treatment.
Patients agreed in writing to the requirements for treatment. Many hip,
knee, and ankle patients required arthroscopic debridement and abrasion
chondroplasty prior to receing IAGH injections. Joint were injected with a
range of dosage of recombinant Human Growth Hormone which ranged
from 2.5 mgm to 10 mgm per injection depending on the size of the joint.
Injections were given weekly for 3 to 15 weeks depending on the response
which was determined by bi-weekly X-rays. Patients were allowed to drop
out of the program at will: none dropped out.
Results: The success rate was as follows: Ankles 95%; knees 87%; hips 60%;
subtalar and talonavicular joints 95%; shoulders 75%; elbows 95%; wrists
95%; base of thumb 75%. There were no complications, allergic reactions,
infections, deep vein thrombosis, pulmonary embolism, or deaths from the
IAGH treatments of over 800 patients.
Conclusions: An alternative treatment to total joint arthroplasty and other
treatments is presented. It utilizes the ability of Growth Hormone injections
to provide Pre-natal Developmental Healing. The advantages of PDH are:
ease of application; lack of complications, side-effects and infection; and
high patient satisfaction. The cost of treating hips, knees, and ankles is
1/4 that of joint replacement arthroplasty which can cost US$35,000.00 for
each joint, without complications. If complications occur with joint arthro-
plasties the cost can easily double. Revision arthroplasty also increase the
costs of total joints. Patients treated with IAGH may need booster injections
once every one to ﬁve years and the cost is small.
The author recommends that IAGH treatment be used before indicating
total joints because if the IAGH treatment is not effective in a small
percentage there are no down-sides. No joints have become worse from
IAGH treatment.
In summary, a treatment which is effective, safe, and economical is
presented as alternative to joint replacements.
Therapy – Intraarticular
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Therapeutic EFFECTS OF INTRA-ARTICULAR ADMINISTRATION OF
ULTRA-PURIFIED LOW ENDOTOXIN ALGINATE ON THE PROGRESSION OF
EXPERIMENTAL OSTEOARTHRITIS IN RABBITS
T. Igarashi, N. Iwasaki, D. Kawamura, N. Tsukuda, A. Minami
Hokkaido Univ., Sapporo, Japan
Purpose: Recent clinical studies have demonstrated no therapeutic effects
of HA on preventing the OA progression. We developed highly puriﬁed
biocompatible alginate, which can drastically reduce the endotoxin level.
Our hypothesis was that the ultra-puriﬁed low endotoxin alginate (UPLE-
alginate) could promote anti-arthritic activity in experimental OA. The aims
of this study were to clarify the effect of the UPLE-alginate administration
on OA progression and on joint lubrication, and to determine the adequate
molecular weight of the UPLE-alginate using a rabbit OA model.
Methods: Three UPLE-alginates were prepared: AL20 (MW 0.43×106 Da),
AL100 (1.0×106 Da), and AL500 (1.70×106 Da) (Mochida Pharmaceutical
Co., Ltd., Tokyo, Japan). For comparison, sodium HA (ARTZ® , Kaken Phar-
maceutical Co., Ltd., Tokyo, Japan) were used. OA model and treatment
protocols. Japanese white rabbits (2.8-3.0 kg) were used according to the
established ethical guidelines approved by the local animal care committee.
To induce OA, ACL transection (ACLT) was performed. All knees were
randomly divided into 5 groups as follows; AL20, AL100, AL500, HA, and
normal saline (NS) groups. Intra-articular injections of a 0.3 ml of each
material (1%) started at 4 weeks for a total of 5 weekly injections. All
animals were euthanized at 9 weeks.
Assessments. Gross morphologic ﬁndings were assessed according to criteria
by Yoshioka et al (n=10 knees). For histological evaluation, the sections
were stained with safranin-O. Cartilage degeneration was quantitatively
analyzed using the scoring system described by Kikuchi (n=8 knees). Six
knees in each group were prepared for mechanical testing. The effect of the
intraarticular injection on joint lubrication was assessed using a pendulum
friction tester designed by our laboratory for small samples. The friction
coeﬃcient was calculated from the obtained data.
Statistical analysis. Signiﬁcant differences among the groups were assessed
by a two-way ANOVA followed by multiple-comparison post hoc tests.
Two-tailed P values less than 0.05 were considered statistically signiﬁcant.
Results: Gross Morphology. The NS and HA groups showed extensive carti-
lage erosion mainly at the medial femoral condyle. The alginate injection
groups exhibited milder degradation than the HA and NS groups. The
AL100 group showed lower severity grades. Severe OA changes of grade
3 (overt ﬁbrillation) and grade 4 (erosion) at the medial femoral condyle
Figure 1
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occurred at a rate of 60%, 63%, 67%, 70%, and 90% in AL100, AL20, AL500,
HA, and NS, respectively.
Histology. In the NS group, loss of the superﬁcial layer, ﬁbrillation, and cleft
were observed. In the HA and the AL500 groups, cartilage degeneration
including ﬁbrillation, ﬁssures, and loss of proteoglycan was observed in the
femoral condyle. An obvious reduction in the severity was found in the
AL100 group. The overall degenerative score of the AL100 group tended to
be the lowest, indicating that AL100 suppressed degradation. The overall
scores of the treatment groups were signiﬁcantly lower than that of the NS
group (AL20, AL100, and AL500 vs NS, p<0.01; HA vs NS, p<0.05).
Friction. The friction coeﬃcients of the AL100 and the AL20 group were
signiﬁcantly lower than that of the NS and the HA group (P<0.05).
Table 1. Histological scores and friction coeﬃcient
Histological score Friction coeﬃcient
NS 21.3±1.3 0.0294±0.0014
HA 17.3±1.2 0.0235±0.0013
AL20 14.9±0.9 0.0148±0.0027
AL100 12.6±0.9 0.0122±0.0037
AL500 15.4±0.9 0.0232±0.0117
Conclusions: The current study is the ﬁrst to examine the inﬂuence of
alginate materials on OA progression in vivo. Our ﬁndings suggest that
intraarticular administration of the UPLE-alginates is effective in prevent-
ing articular cartilage degeneration and on improving joint lubrication of
OA knees induced by ACLT. In terms of molecular weight dependency,
AL100 (1.0×106 Da) has more therapeutic effects on OA progression.
Based on these results, we reasonably conclude that the UPLE-alginates,
especially AL100, have promising potential for becoming an effective agent
of intraarticular injection for preventing OA progression.
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EFFECTS OF INTRA-ARTICULAR INJECTIONS OF HYLAN GF-20 ON SERUM
AND URINE BIOMARKERS IN PATIENTS WITH KNEE OSTEOARTHRITIS:
THE BIOVISCO STUDY
T. Conrozier1, X. Chevalier2, J.-C. Balblanc3, P. Richette4, F. Rannou5,
D. Mulleman6, B. Maillet7, J.-F. Maillefert8, P. Mathieu1, Y. Henrotin9,
E. Vignon1
1centre Hosp. Lyon Sud, Pierre Bénite, France; 2Hôpital Henri Mondor, Créteil,
France; 3centre Hosp. de Belfort, Pierre Bénite, France; 4Hôpital Lariboisiere,
Paris, France; 5Hôpital Cochin, Paris, France; 6Hôpital Trousseau, Tours,
France; 7Clinique Sainte Odilon, Moulins, France; 8centre Hosp. de Dijon, Dijon,
France; 9Hôpital Universitaire, Liège, Belgium
Purpose: Viscosupplementation (VS) by intra articular (IA) injection of
hyaluronic acid (HA) is widely used to reduce pain in patients with
knee osteoarthritis (K-OA). However little is known on its effect on joint
metabolism as well as on its possible structure modifying effect. Objectives:
To investigate the effect of VS on circulating OA biomarkers in patients
with K-OA.
Methods: Prospective open label study. 51 patients with unilateral symp-
tomatic K-OA (ACR criteria; Kellgren-Lawrence grade I to IV) received an
IA injection of 2mL of HA (hylan GF-20) IA injection on days (D) 1, 7, 14
and were followed 3 months. At D-15 patients were examined and X-rays
were performed, in order to exclude patients with bilateral K-OA, or those
with more than 3 OA joints including the target knee. From D-15 to D90
concomitant therapies were unchanged. Walking pain (WP) on VAS was
obtained at each visit. Clinical response was deﬁned as a WP decrease >30
mm between D1 and D90 (50% improvement). Urine (U) and serum (S)
samples were obtained, using a standardized procedure, 2 weeks before
the ﬁrst injection (D-15), then at D1 (1st injection), D30 and D90. S-C2C,
S-Cartilage oligomeric protein (S-COMP), S-HA, S-CS846 epitope, S-type II
collagen propeptide (S-PIICP) and U-type II collagen C telopeptide (CTX
II/creatinin) were assayed. Variations over time for each biomarker were
studied using Wilcoxon rank sum test.
Results: 45 patients (mean age 57.7, mean BMI 26.7) were analyzed. At
baseline there was no difference between ITT and per-protocol population.
Between D-15 and D1 there was no signiﬁcant difference for any biomark-
ers (all p>0.05), indicating a good reproducibility in S and U measurements
and the absence of spontaneous variation over time. At D1 WP was
correlated with U-CTX II/creat (p=0.006). Between D1 and D90: Mean (SD)
WP decreased from 57.7 (15.4) to 29.3(22.9) mm (p<0.0001). No variation
was found for any S-biomarker. By contrast U-CTX II/creat was reduced
by 20.5% and decreased signiﬁcantly between D1 and D90 (385.1 vs 306.0
ng/mmol creat; p= 0.02). Furthermore U-CTX II and S-HA levels at baseline
were both but independently predictive of clinical response to treatment
(p=0.03 and p=0.02) even after adjustment for age, gender and BMI. Further
more in logistic regression including age, BMI, bilaterality, KL grade, OA at
other joints, DMOADS consumption and U-CTX II/creat at baseline, there
was a signiﬁcant correlation between clinical response and U-CTX II/creat
level variation (p=0.03).
Conclusions: This study suggests that hylan IA injections are able to mod-
ify the knee joint metabolism in patients with OA resulting in a decrease
in urine CTX II concentrations, particularly in patients with the highest
levels of U-CTX II and HA before treatment. Further studies coupling
biomarkers and imaging techniques are needed to investigate the possible
chondroprotective effect of hylan in K-OA.
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CHARACTERIZATION OF SUSTAINED RELEASE NATIVE AND MODIFIED
HUMAN SFLT01 FORMULATION FOR INTRAARTICULAR DELIVERY TO
TREAT OA PAIN
W. Cheng1, J. Stefano2, D. Li2, J. Kyazike2, K. Boudanova2, H. Qiu2, L. Hou2,
M. O’Callaghan2, V. Kraus1, G. Matthews2
1Duke Univ., Durham, NC; 2Genzyme Corp., Framingham, MA
Purpose: VEGF is both a potent angiogenic and vascular permeability factor
that is crucial in endochondral ossiﬁcation involved in bone formation and
remodeling. We hypothesize that osteoarthritis (OA) pain-associated bone
marrow lesions, effusion, and synovitis are in part, driven by VEGF medi-
ated increases in vascular permeability. Soluble fms-link tyrosine kinase 1
(sFlt1), a variant of VEGF receptor Flt1, can potentially block the function of
VEGF. Our previous work demonstrated that VEGF inhibition using virally
delivered sFlt decreased synovitis and pain marker expression in a rabbit
OA model. However, the biological joint half life of recombinant human
sFlt01, a VEGF neutralizing Fc fusion protein, was demonstrated to be just
a few hours. In order to prolong the joint half life of sFlt01, we constructed
a modiﬁed delivery form of this protein, veriﬁed its bioactivity, and con-
ﬁrmed enhanced stability compared to sFlt01 in accelerated stability tests
up to 3 months.
Methods: Modiﬁed sFlt delivery construct TCEP reduction and CuCl2 ox-
idation were used to create a dimerized modiﬁed sFlt delivery construct,
which was subsequently column puriﬁed and compared to native sFlt as
well as the monomer forms of the modiﬁed delivery construct on silver
stained SDS PAGE gels.
In vitro VEGF ELISA binding assay A two-fold serial dilution of sFlt01 or
the modiﬁed sFlt delivery construct starting from 10,000 pM was made
in assay medium (M199 media + 5% FBS + 1x Penn/Strep). VEGF165 (10
pM) was then incubated with the serial dilutions. Unbound VEGF for each
dilution was measured by ELISA to identify whether any shift had occurred
between VEGF neutralization by the modiﬁed sFlt delivery construct vs.
native sFlt01 control.
Accelerated stability test Modiﬁed sFlt delivery construct (0.25 mg/ml)
was incubated in PBS with 1X HALT protease inhibitor cocktail with EDTA
(Pierce) at 45°C and aliquots drawn and ﬂash frozen at -80°C. Unmodiﬁed
sFlt01 at the same concentration was used as a control. The samples were
collected over different time points in both 36 and 94 day stability tests.
The samples with or without PNGase F treatment was further analyzed by
silver-stained reducing SDS PAGE.
Results: TCEP reduction and CuCl2 oxidation resulted in successful dimer-
ization of the modiﬁed sFlt delivery construct.
TCEP reduced protein monomer showed ∼35 fold higher EC50 vs. native
sFlt01 whereas Cu2+ oxidized dimer showed 2.2 - fold high EC50 compared
to sFlt01.
From the accelerated stability test data, sFlt01 control showed increase
amount of ∼35 kDa product as well as high molecular weight of ∼115
kDa product in silver stained reducing SDS PAGE without PNGase treat-
ment. The modiﬁed sFlt delivery construct showed greater stability at
elevated temperature, generating less high molecular weight aggregate and
fragmentation compared to sFlt01 control at both 36 and 96 days.
Conclusion: The generated modiﬁed sFlt delivery construct expressed from
HEK293 can be eﬃciently dimerized.
Copper-generated protein dimer retains high aﬃnity for VEGF binding,
comparable to native sFlt01.
The modiﬁed sFlt delivery construct appears more stable at elevated tem-
